Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Concordia Pharmaceuticals
Concordia Pharmaceuticals Reports Encouraging Clinical Data in Patients with K-Ras Mutations Treated with First-in-Class Ras Antagonist, Salirasib
June 2nd, 2009
Concordia Pharmaceuticals reported encouraging new clinical data for salirasib, its novel small-molecule direct Ras antagonist, from two ongoing clinical trials – one in patients with advanced pancreatic cancer, and another in patients with advanced non-small cell lung cancer (NSCLC). The results in pancreatic cancer and NSCLC were reported in two abstracts (#4529 and 8012 respectively) released in advance of the American Society of Clinical Oncology 2009 Annual Meeting, and will be presented by investigators in two separate poster presentations. In a phase 1/2 trial in patients with advanced pancreatic cancer, salirasib treatment resulted in median survival of >10.8...
Source: Cancer Weekly (2009-06-02)
|
